Evidence map›Paper›PMID 35290718›Full record

ArticleJournal of diabetes investigation2022

Factors affecting glycemic control in diabetes mellitus complicated by autoimmune pancreatitis.

Nozomi Harai, Akihiro Nishimura, Kimio Matsumura, Yuya Suzuki, Shota Kikuno, Tetsuro Kobayashi, Kaoru Nagasawa, Yasumichi Mori

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nozomi HaraiDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5273-4602
Akihiro NishimuraDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9347-1228
Kimio MatsumuraDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-7031-5014
Yuya SuzukiDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
Shota KikunoDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
Tetsuro KobayashiDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4364-2527
Kaoru NagasawaDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
Yasumichi MoriDepartment of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
Toranomon Hospital · JPUniversity of Yamanashi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS/

introductionTo investigate factors influencing glycemic control in diabetes mellitus complicated by autoimmune pancreatitis. MATERIALS AND

methodsThis retrospective cohort study investigated 33 patients with diabetes mellitus complicated by autoimmune pancreatitis who had received steroid therapy at Toranomon Hospital between January 1, 2011, and December 31, 2020. The course of glycemic control at 12 months after starting steroids was classified into three groups: Improved, Unchanged, or Worsened. Factors affecting these groups were investigated. Furthermore, we created two scores: (1) time of diabetes mellitus onset and baseline body mass index; (2) time of diabetes mellitus onset and baseline C-peptide index. Diabetes mellitus occurring at the same time as autoimmune pancreatitis, body mass index ≥22 kg/m

resultsTen patients were in the Improved group, 10 were in the Unchanged group, and 13 were in the Worsened group. The baseline body mass index and baseline C-peptide index were lower in the Worsened group than in the Improved group (P < 0.05 each). In addition, the scores were lower in the Worsened group than in the other groups (P < 0.05).

conclusionsPatients with a lower baseline body mass index and a decreased baseline C-peptide index may experience worse glycemic control on steroid therapy.

Indexed as

Autoimmune PancreatitisDiabetes MellitusDiabetes Mellitus, Type 2Blood GlucoseC-PeptideGlycated HemoglobinGlycemic ControlHumansRetrospective StudiesSteroidsBlood GlucoseC-PeptideGlycated HemoglobinSteroidsAutoimmune pancreatitisDiabetes mellitusSteroid

Identifiers

PMID35290718
PMCPMC9340874
OpenAlexW4220663599

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.